Loading
Veteran myeloma trialist who helped bring proteasome inhibitors and bispecifics to patients.
Sundar Jagannath is Director of the Center of Excellence for Multiple Myeloma at The Mount Sinai Hospital and Tisch Cancer Institute. He is a veteran myeloma trialist who helped bring proteasome inhibitors and bispecific antibodies to patients, serving as principal investigator across bortezomib, carfilzomib and teclistamab-era studies. His selected paper reports bortezomib alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. He directs Mount Sinai's myeloma centre and continues to work on novel agents and bispecific antibodies.
| Title | Journal | Year |
|---|---|---|
| Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma | British Journal of Haematology | 2005 |
Shares Carfilzomib, Teclistamab, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Bortezomib, Multiple myeloma.
Shares Carfilzomib, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/